

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1. (Currently amended) A method of modulating ~~a biological function of an endothelial cell or hematopoietic T-cell activation~~, comprising introducing in vitro ~~into the cell~~ an agent that inhibits binding of ~~a PDZ protein and a PL protein LPAP and TIP-1~~ ~~in the~~ ~~into a T-cell~~, thereby modulating activation of the T-cell. ~~the biological function~~, wherein

\_\_\_\_\_ the PL is LPAP and

\_\_\_\_\_ the PDZ is TIP1.

2-4. (Canceled)

5. (Currently amended) The method of ~~claim 2~~ claim 1, wherein the agent is a peptide that (i) is 4- 25 amino acids in length and (ii) comprises comprising a sequence of at least the carboxy-terminal two residues of ~~the PL protein LPAP~~.

6. (Currently amended) The method of ~~claim 4~~ claim 5, wherein the agent is a peptide comprising a sequence of at least the carboxy-terminal three residues of ~~the PL protein LPAP~~.

7. (Currently amended) The method of ~~claim 4~~ claim 1, wherein the agent is a small molecule or peptide mimetic of the carboxy-terminus of ~~the PL protein LPAP~~.

8-20. (Canceled)

21. (New) The method of claim 5, wherein the peptide is 12-25 amino acids in length.